Non-HDL-C: new tool uses it to assess long-term CVD risk

  • Brunner FJ & al.
  • Lancet
  • 03.12.2019

  • von Emily Willingham, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Non-high-density lipoprotein cholesterol (HDL-C) is linked to long-term cardiovascular disease (CVD) risk, according to the authors of this multinational study.

Why this matters

  • These authors offer a “simple” tool that uses non-HDL-C for assessing risk and evaluates possible benefits of starting lipid-reducing therapy.

Key results

  • With increasing serum non-HDL-C, 30-year CVD rates increased:
    • 7.7% with
    • 12.8% with
  • Steepest risk increases seen in those under age 45 years at baseline.
  • They found that reducing non-HDL-C by 50% decreased CVD event risk by age 75 years, with increasing benefit with earlier reductions.

Study design

  • Data from the Multinational Cardiovascular Risk Consortium, 19 countries in Europe, Australia, and North America.
  • 398,846 participants from 38 cohorts; of these, 199,415 were in the derivation cohort and 199,431 were used for validation.
  • Funding: EU Framework Programme, others.

Limitations

  • Only baseline lipid values used.
  • Most participants were of European ancestry.